Kornimate/medical-research-clean huggingface dataset:
iron fish for dominican republic (dr) infants

Conditions: Iron-deficiency; Iron Deficiency Anemia

Summary: this study evaluates the feasibility of cooking with an iron ingot, lucky iron fish™ (lif), and evaluate the natural history of hemoglobins and iron status among infants of families using this iron ingot in a population with a high prevalence of iron-deficiency anemia. participants are mother-infant dyads, and are randomized to one of two arms: lucky iron fish™or enhanced standard of care.

iron deficiency and iron-deficiency anemia contribute significantly to global pediatric morbidity, predominantly affecting women and preschool aged children in resource-limited settings. iron-deficiency in infancy has been linked to neurodevelopmental delay. current methods of iron repletion and supplementation have proved inadequate. the lucky iron fish™ is a iron ingot, the size of a small bar of soap, that is made of pure iron. when boiled, it releases bioavailable iron into water, which is then used for food preparation and/or drinking. participants in the lif arm are instructed to acidify the water with citrus juice (provided). all participants are followed at the same intervals to complete questionnaires and study-related labs.

Eligibility criteria:
inclusion criteria: * mother ≥ 18 years of age * a newborn delivered at ≥ 35 weeks * infant child followed by (or will be followed by) affiliated clinic (niños primeros en salud \[nps\]) or infant delivered at angel ponce, the local maternity hospital of consuelo, dominican republic. * mother is spanish speaking * mother permission is provided (informed consent) exclusion criteria: * maternal history of sickle cell disease (homozygous) * concurrent enrollment in related study of lif on anemia of young children (chop study #16-012631). * inability to understand and speak spanish * severe cognitive impairment or severe psychiatric disease which would prohibit the answering of study questions

Keywords: iron-deficiency iron deficiency anemia
impact of regional vibration application and flow mediated dilation on brachial artery hemodynamics

Conditions: Vasodilation; Diabetes Mellitus, Type 2

Summary: application of vibration has been previously shown to affect tissue perfusion and utilized in different branches of medicine. little is known about the acute impact of vibration application on peripheral artery hemodynamics. in this study, investigators intend to assess: 1. vibration induced hemodynamic changes in brachial artery in non-diabetic patients and compare the characteristics of these alterations with flow mediated dilation mediated changes in same cohort. 2. compare the characteristics of vibration mediated hemodynamic alterations in diabetic and non-diabetic subgroups.

background and rationale: vibration application has been previously shown to affect tissue perfusion and utilized in different branches of medicine. however, previous studies have mainly focused on the impact of vibration on skin perfusion or vibration with active muscle contractions, therefore couldn't truly demonstrate acute impact of local vibration application on peripheral arteries. in addition to that, as a population that is prone to develop vascular problems, it is not known whether diabetic patients have comparable response to vibration application with non-diabetic population. objectives: in this study, investigators aim to demonstrate and compare hemodynamic alterations in brachial artery with paired measurements pre- and post- vibration application and compare the characteristics of these changes with those of flow-mediated dilation in a non-diabetic cohort. additionally, differences and similarities in vascular hemodynamic response to vibration in diabetic and non-diabetic subgroups are intended to be elucidated. methods: flow mediated dilatation and vibration will be applied after the participants will abstain from alcohol, caffeine and nicotine for 24 hours. flow mediated dilatation (fmd) will be induced via 5 min cuff inflation below left elbow at supra-systolic pressures (50mmhg above pre-application systolic pressure). vibration will be applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of fmd. left brachial artery flow will be measured with pulsed doppler and diameter will be measured via 2d ultrasonographic imaging at 0th, 2nd, 4th, 6th, 8th minutes.throughout the entire application and measurement periods, patients will be continuously monitored with electrocardiogram.

Eligibility criteria:
inclusion criteria: * 18 - 80 * sinus rhythm in ecg * ejection fraction \> %35 * informed consent exclusion criteria: * unstabile angina * certain or suspected subclavian artery or brachial artery atherosclerotic disease (assessed with usg) * heart failure ( new york heart association iii - iv) * atrial fibrillation or frequent extrasystoles in ecg.

Keywords: vibration peripheral artery hemodynamics diabetes mellitus
external ankle supports - 3d motion analysis

Conditions: Chronic Ankle Instability

Summary: untreated ankle sprains often remain symptomatic and may end in chronic instability. the aim of our study is to quantify the stabilizing effect of different devices. through the use of a foot measurement model in 3d motion analysis the influence of the devices with respect to a mechanical effect is examined by means of different tests. the dynamic postural control is quantified. the hypothesis was that the devices would stabilize differently the foot segments.


Eligibility criteria:
inclusion criteria: * chronic ankle instability * "giving way" * repeated ankle sprains exclusion criteria: * other injuries of the lower extremities * surgery on the lower extremities
prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients

Conditions: Peripheral Neuropathy Due to Chemotherapy

Summary: paclitaxel-induced peripheral neuropathy (pipn) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure. a lot of interventions have been tried to prevent pipn, ensure complete administration of the chemotherapy cycles, and increase the survival rate. one of the promising interventions in the prevention of pipn is losartan. losartan is an angiotensin receptor blocker (arbs) and is used to treat hypertensive patients. there is strong evidence from different preclinical studies and retrospective cohort studies that losartan has a neuroprotective effect. the purpose of our study is to investigate the efficacy of losartan in the prevention of peripheral neuropathy associated with paclitaxel treatment in breast cancer patients.


Eligibility criteria:
inclusion criteria: * females older than 18 years diagnosed with biopsy-confirmed breast cancer (early breast cancer eligible for adjuvant or neoadjuvant) who are scheduled to receive paclitaxel 80 mg/m2. exclusion criteria: * known hypersensitivity to losartan. * not known hypertensive patients * not known diabetic patients * treatment with losartan/arbs/ace-i prior to the study. * previous neuropathy * renal impairment (serum creatinine \> 2 mg/dl) * significant liver disease: liver enzymes 2 folds the upper normal limit * metastatic breast cancer * pregnancy or lactation * taking other medication for neuropathic pain * significant hypotension

Keywords: paclitaxel breast cancer peripheral neuropathy
a trial to assess the effect of liraglutide on gastric emptying in healthy obese volunteers

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in europe. the aim of this clinical trial is to investigate the effect of liraglutide on gastric emptying, energy expenditure and appetite, and to evaluate liraglutide pharmacokinetics in non-diabetic obese volunteers. the trial is designed as a two-period, six-sequenced, crossover trial where the trial participant will enter two treatment periods with a wash-out period of 6-8 weeks.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 30.0-40.0 kg/m2 * stable body weight (below 5 kg body weight change during past 3 month) * fasting plasma glucose below 7.0 mmol/l exclusion criteria: * presence or history of cancer or any clinically significant cardiac, metabolic, renal, gastrointestinal, hepatic, endocrine, dermatological, haematological, or psychiatric diseases or disorders, considered by the investigator to have influence of the results of this trial * history of chronic pancreatitis or idiopathic acute pancreatitis * current or history of treatment with medications that may cause significant weight gain, within 12 months prior to screening * use of weight lowering pharmacotherapy within the last 3 months prior to trial start * previous or scheduled (during the trial period) surgical treatment for obesity * diagnosed type 1 or type 2 diabetes * smoking habitually as judged by the investigator * females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods if not sterile or post-menopausal
treatment of ghd associated with chf

Conditions: Heart Failure; Growth Hormone Deficiency

Summary: aim of the current study is to assess the cardiovascular effects of gh replacement therapy in patients with coexisting ghd and chf

multiple anabolic deficiencies are common in chronic heart failure (chf) and identify subgroups of patients with higher mortality. apart from chf, gh deficiency (ghd) per se increases cardiovascular mortality in the general population and low igf-1 levels in the general population predict the development of ischemic heart disease and chf. ghd modifies cardiac size and function, through a reduction in both myocardial growth and cardiac performance. the investigators therefore completed 2 studies aimed at evaluating the clinical status, neurohormonal parameters, exercise capacity, vascular reactivity, and left ventricular architecture and function in patients with ghd and chf, at baseline and after 6 months of gh replacement therapy. they subsequently extended the observation period up to 48 months. at 6-months, gh replacement therapy improved clinical status and exercise capacity, as shown by a significant reduction of the minnesota living with heart failure questionnaire score, increased peak oxygen consumption and exercise duration, and flow mediated vasodilation of the brachial artery. no major adverse events were reported in the patients receiving gh. however, the encouraging results of these studies are limited by the lack of a double-blind, placebo-controlled design, insofar as the investigators performed a randomized controlled, single-blind study.

Eligibility criteria:
inclusion criteria: 1. patients of either sex affected by chf nyha class i-iii, secondary to ischemic or idiopathic di-lated cardiomyopathy; 2. age range 18-85 years; 3. stable and optimal medical therapy for at least three months prior to randomization, including ace inhibitors or at1 antagonists and beta-blockers (unless untolerated); 4. lv ejection fraction 40% or less and lv end-diastolic dimension 55 mm or more; 5. gh deficiency diagnosed with ghrh + arginine provocative test; 6. signed informed consent. exclusion criteria: 1. inability to perform a bicycle exercise test; 2. poorly controlled diabetes mellitus (hba1c \>8.5) and/or active proliferative or severe non-proliferative diabetic retinopathy; 3. active and/or history of malignancy; 4. unstable angina or recent myocardial infarction (less than six months); 5. severe liver or kidney disease (serum creatinine levels \>2.5 mg/dl

Keywords: growth hormone placebo exercise capacity vascular reactivity lv function prognosis
predictive algorithm for evaluation and intervention in sepsis

Conditions: Sepsis; Septic Shock; Severe Sepsis

Summary: in this prospective study, the ability of a machine learning algorithm to predict sepsis and influence clinical outcomes, will be investigated at cabell huntington hospital (chh).


Eligibility criteria:
inclusion criteria: * all adult patients visiting the emergency department, or admitted to the participating intensive care unit (icu) wards of cabell huntington hospital will be eligible. exclusion criteria: * all patients younger than 18 years of age will be excluded.
effect of therapeutic touch and mother's voice on pain and comfort level during nasal cpap application

Conditions: Preterm Infants; Nasal Continuous Positive Airway Pressure; Pain Management

Summary: aim: this study was conducted to evaluate the effects of therapeutic touch and mother's voice on pain and comfort levels of preterm infants during nasal cpap application.

aim: this study was conducted to evaluate the effects of therapeutic touch and mother's voice on pain and comfort levels of preterm infants during nasal cpap application. design and method: the study, which used a randomized controlled trial, included 124 preterm neonatal infants a gestational age of 28- 37 weeks and received nasal cpap. the infants were treated with mother's voice, therapeutic touch, and mother's voice+ therapeutic touch. the neonatal infant pain scale (nips) and premature infant comfort scale (pics) scores of the infants were measured before, during and after the nasal cpap application.

Eligibility criteria:
inclusion criteria: * being checked in at neonatal intensive care unit * being in the gestational ages of 28 to 37 weeks * having nasal cpap exclusion criteria: * having neurological disorders * having comorbidity * receiving sedation or analgesics * having congenital anomaly * receiving extra invasive procedures or surgical intervention * being diagnosed with hearing loss

Keywords: nasal continuous positive airway pressure (ncpap) therapeutic touch mother's voice pain comfort
orthodontic treatment on oral microbiota and salivary proteins

Conditions: Orthodontics; White Spot Lesions [Initial Caries] on Smooth Surface of Tooth; Caries, Dental

Summary: study on the changes in oral microbiota during orthodontic treatment in patients aged 8-18 years. orthodontic patients treated at stomatology hospital of xi'an jiaotong university from march 2025 to march 2027 will be recruited. prior to orthodontic treatment, routine preoperative examinations will be conducted, informed consent forms will be signed, baseline oral conditions will be recorded, and oral and psychological-related questionnaires will be completed. patients will be informed of the need for regular oral hygiene check-ups, caries risk assessments will be performed, and plaque, saliva, and intraoral photographs will be collected. during orthodontic treatment, plaque samples will be collected every 3 months, and saliva samples will be collected every 6 months until the treatment is completed to evaluate the changes in oral microbiota throughout the orthodontic process.


Eligibility criteria:
inclusion criteria: * no carries and white spot * no missing teeth * no history of oral treatment * no malocclusion * no systemic diseases exclusion criteria: * antibiotic use in the past three months * a history of long-term medication use * a history of dental fillings * unable to attend regular follow-ups

Keywords: microbiota
effects of frax+sarc-f pre-screening on preventing fragility fracture and fall in community-dwelling older adults

Conditions: Age Related Osteoporosis; Fall

Summary: hip fragility fractures are a major threat to functional independence in older adults locally and globally. in hong kong, the prevalence of osteoporosis and osteopenia in people aged \>50 years were reported to be as high as 37% and 52%, respectively. the major challenge in fragility fracture prevention is that fragility fracture is caused by the combination of osteoporosis and propensity to fall, and both of these conditions are multifactorial. ample evidence shows that fall risks can be reduced by well-designed exercises, and osteoporosis can be effectively diagnosed by dual-energy x-ray absorptiometry imaging (dxa) and treated with anti-osteoporosis medication. lifestyle modifications e.g. diet, optimal physical activity, environmental safety can also help to prevent falls or improve bone health. the brief fracture risk assessment tool (frax) and sarc-f provide a low cost of prescreening for fracture risk and sarcopenia, respectively. using sarc-f in conjunction with frax has increased sensitivity for hip fracture risk prediction. frax+sarc-f may help increase the public awareness of osteoporosis and get the at-risk group to receive diagnostic tests and be treated. this model should fit in well with the coming district health centres across hong kong.

participants will be randomly assigned to either the pre-screening or control group in a 1:1 ratio. independent personnel not involved in data collection or intervention will perform and conceal the randomization using an online data server. research assistants who are blinded to the group allocation will conduct all the baseline assessments and subsequent event surveillance. all data will also be entered and checked by the blinded research assistants. all procedures concur with the declaration of helsinki (2013).

Eligibility criteria:
inclusion criteria: * aged ≥ 65 years * living in the community exclusion criteria: • cannot follow the instruction
high-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for hiv-positive patients with malignant diseases indicating an hsct

Conditions: AIDS-related Lymphoma; HIV Infections

Summary: patient stem cells will be mobilized with induction chemotherapy (r)-ice and g-csf. if sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous cd34+ cells transduced with an antiviral vector (m87o). if autologous cd34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. to minimize risk of transplant failure, a second unmodified cd34+ cell transplant will be given one week after the first transplant.


Eligibility criteria:
inclusion criteria: * male and female patients of any ethnic group aged between 18 and 65 years * hiv-positive patients with malignant diseases of the blood (nhl, hodgkin disease, plasmocytoma, acute and chronic leukaemia) who failed to achieve complete remission (cr) after standard-dose first-line chemotherapy or had a chemosensitive relapse after an initial cr * patients must receive haart exclusion criteria: * any of the following conditions: * congestive heart failure (nyha \> ii) * documented ebv, hbv or hcv infection (only for allogeneic pbsct) * creatinine clearance \< 60 ml/min * left ventricular ejection fraction \< 40% * bilirubin \> 2 mg/dl * severe opportunistic infection * more than 10% of bone marrow involved with lymphoma * between 2 and 5 10\^6 autologous cd34+ cells/kg bw obtained after leukapheresis and cd34 enrichment * women of child.bearing potential not under adequate contraceptive protection * women who are pregnant or breast feeding * known history of drug-, medication- or alcohol abuse within the last 12 months preceding the study * participation in another study with an investigational product within less than one month prior to this study * simultaneous participation in a study with an investigational drug * presence of any disease likely to require procedures altering the schedule of the protocol * patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in the opinion of the investigator * patients with limited mental capacity to the extent that he/she cannot provide informed consent or information regarding adverse events of the study medication * patients with any clinically meaningful renal, hepatic, respiratory or cardiovascular disease * patients who have previously been admitted to this study * patients who will not accept transfusions of blood products

Keywords: aids hiv lymphoma stem cell transplantation gene-modified stem cells treatment experienced
mri radiomics combined with pathomics on the prediction of molecular classification and prognosis of endometrial cancer

Conditions: Endometrial Neoplasms

Summary: molecular typing provides accurate information for the diagnosis, treatment and prognosis prediction of endometrial cancer, which has important clinical significance. however, due to its high cost and complicated process, it is difficult to be widely used in clinical practice. based on the artificial intelligence method, this study fused the characteristics of mri radiomics and pathomics, combined with the clinical pathological information, built a model to predict the molecular typing and prognosis, analyzed the biological characteristics of endometrial cancer from the multi-scale level, guided the personalized and precise diagnosis and treatment, in order to improve the prognosis of patients.

in this project, 150 cases of endometrial cancer were retrospectively collected, and 200 cases of endometrial cancer will be prospectively collected. all patients were pathologically confirmed and underwent promise molecular typing. before treatment, all patients completed abdominal mri. based on artificial intelligence technology, image features were extracted from magnetic resonance imaging, pathological features were extracted from pathological data, and clinical pathological data were collected at the same time. the treatment effect, recurrence and metastasis of patients were followed up, and the five-year survival rate and five-year progression free survival rate were calculated. it is proposed to focus on the following research: 1. construction of molecular typing and prognosis prediction model of endometrial cancer based on magnetic resonance imaging radiomics 2. construction of molecular typing and prognosis prediction model of endometrial cancer based on pathomics. 3. construction of a prediction model for molecular typing of endometrial cancer by integrating pathomics and radiomics.

Eligibility criteria:
inclusion criteria: * •pathologically confirmed as endometrial malignant tumor with complete pathological h＆e stained sections; * age ≥ 18 years and ≤ 80 years; * no other malignant cancers was found; * the complete immunohistochemical and second-generation sequencing results can be used for the molecular typing of promise; * magnetic resonance examination was performed within 2 weeks before treatment, and there was at least one measurable lesion according to recist 1.1 criteria. exclusion criteria: * • the image quality is poor or the tumor is too small due to serious graphic artifact and degeneration, and the roi cannot be accurately delineated; * patients who received any antitumor therapy before surgery; * diagnostic endometrial biopsy before mri

Keywords: endometrial neoplasms machine learning radiomics pathomics tcga classification